Metal-free and MRI visible theranostic lyotropic liquid crystal nitroxide-based nanoparticles

Biomaterials

Volumn 33, Issue 9, 2012, Pages 2723-2733

  Muir, Benjamin W ^a   Acharya, Durga P ^a   Kennedy, Danielle F ^a   Mulet, Xavier ^a,b   Evans, Richard A ^a   Pereira, Suzanne M ^a   Wark, Kim L ^a   Boyd, Ben J ^b   Nguyen, Tri Hung ^b   Hinton, Tracey M ^a   Waddington, Lynne J ^a   Kirby, Nigel ^c   Wright, David K ^d   Wang, Hong X ^d   Egan, Gary F ^d   Moffat, Bradford A ^d  

^a CSIRO   (Australia)

^b MONASH UNIVERSITY   (Australia)

^c AUSTRALIAN SYNCHROTRON   (Australia)

^d UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Contrast agent; Cubosome; Cytotoxicity; High throughput; Lyotropic liquid crystal; Maximum tolerated dose

Indexed keywords

CONTRAST AGENT; CUBOSOMES; HIGH-THROUGHPUT; LYOTROPIC LIQUID CRYSTAL; MAXIMUM TOLERATED DOSE;

COORDINATION REACTIONS; CYTOTOXICITY; GADOLINIUM; GADOLINIUM COMPOUNDS; HEAVY METALS; LIQUID CRYSTALS; PARAMAGNETISM; RATS; TOXICITY;

NANOPARTICLES;

GADOLINIUM; HEAVY METAL; NANOPARTICLE; NITROXIDE; PROTON;

ARTICLE; CYTOTOXICITY; IN VITRO STUDY; IN VIVO STUDY; LIQUID CRYSTAL; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL;

ANIMALS; CELL DEATH; CHO CELLS; CRICETINAE; CRICETULUS; CRYOELECTRON MICROSCOPY; FATTY ALCOHOLS; HEK293 CELLS; HUMANS; LIQUID CRYSTALS; MAGNETIC RESONANCE IMAGING; MALE; METALS; NANOPARTICLES; NITROGEN OXIDES; RATS; RATS, SPRAGUE-DAWLEY; SCATTERING, SMALL ANGLE; SYNCHROTRONS; X-RAY DIFFRACTION;

RATTUS;

EID: 84855935405     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2011.12.018     Document Type: Article

References (52)

1. Chertok B., David A.E., Moffat B.A., Yang V.C. Substantiating invivo magnetic brain tumor targeting of cationic iron oxide nanocarriers via adsorptive surface masking. Biomaterials 2009, 30(35):6780-6787.
2. Chertok B., Moffat B.A., David A.E., Yu F., Bergemann C., Ross B.D., et al. Iron oxide nanoparticles as a drug delivery vehicle for MRI monitored magnetic targeting of brain tumors. Biomaterials 2008, 29(4):487-496.
3. Moffat B.A., Reddy G.R., McConville P., Hall D.E., Chenevert T.L., Kopelman R.R., et al. Anovel polyacrylamide magnetic nanoparticle contrast agent for molecular imaging using MRI. Mol Imaging 2003, 2(4):324-332.
4. Lin J.J., Chen J.S., Huang S.J., Ko J.H., Wang Y.M., Chen T.L., et al. Folic acid-pluronic F127 magnetic nanoparticle clusters for combined targeting, diagnosis, and therapy applications. Biomaterials 2009, 30(28):5114-5124.
5. Reddy G.R., Bhojani M.S., McConville P., Moody J., Moffat B.A., Hall D.E., et al. Vascular targeted nanoparticles for imaging and treatment of brain tumors. Clin Cancer Res 2006, 12(22):6677-6686.
6. Farokhzad O.C., Cheng J.J., Teply B.A., Sherifi I., Jon S., Kantoff P.W., et al. Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy invivo. Proc Natl Acad Sci USA 2006, 103(16):6315-6320.
7. Kono K., Nakashima S., Kokuryo D., Aoki I., Shimomoto H., Aoshima S., et al. Multi-functional liposomes having temperature-triggered release and magnetic resonance imaging for tumor-specific chemotherapy. Biomaterials 2011, 32(5):1387-1395.
8. Shubayev V.I., Pisanic T.R., Jin S.H. Magnetic nanoparticles for theragnostics. Adv Drug Del Rev 2009, 61(6):467-477.
9. Hahn P.F., Saini S. Liver-specific MR imaging contrast agents. Radiol Clin North Am. 1998, 36(2):287+.
10. Caravan P., Ellison J.J., McMurry T.J., Lauffer R.B. Gadolinium(III) chelates as MRI contrast agents: structure, dynamics, and applications. Chem Rev 1999, 99(9):2293-2352.
11. Caravan P. Strategies for increasing the sensitivity of gadolinium based MRI contrast agents. Chem Soc Rev 2006, 35(6):512-523.
12. Laurent S., Elst L.V., Muller R.N. Comparative study of the physicochemical properties of six clinical low molecular weight gadolinium contrast agents. Contrast Media Mol Imaging 2006, 1(3):128-137.
13. Sadowski E.A., Bennett L.K., Chan M.R., Wentland A.L., Garrett A.L., Garrett R.W., et al. Nephrogenic systemic fibrosis: risk factors and incidence estimation. Radiology 2007, 243(1):148-157.
14. Srinivas M., Cruz L.J., Bonetto F., Heerschap A., Figdor C.G., de Vries I.J.M. Customizable, multi-functional fluorocarbon nanoparticles for quantitative invivo imaging using F-19 MRI and optical imaging. Biomaterials 2010, 31(27):7070-7077.
15. Ahrens E.T., Flores R., Xu H.Y., Morel P.A. Invivo imaging platform for tracking immunotherapeutic cells. Nat Biotechnol 2005, 23(8):983-987.
16. Keana J.F.W., Pou S., Rosen G.M. Nitroxides as potential contrast enhancing agents for MRI application: influence of structure on the rate of reduction by rat hepatocytes, whole liver homogenate, subcellular fractions, and ascorbate. Magn Reson Med 1987, 5(6):525-536.
17. Keana J.F., Pou S. Nitroxide-doped liposomes containing entrapped oxidant: an approach to the " reduction problem" of nitroxides as MRI contrast agents. Physiol Chem Phys Med NMR 1985, 17(2):235-240.
18. Hyodo F., Chuang K.H., Goloshevsky A.G., Sulima A., Griffiths G.L., Mitchell J.B., et al. Brain redox imaging using blood-brain barrier-permeable nitroxide MRI contrast agent. JCereb Blood Flow Metab 2008, 28(6):1165-1174.
19. Conn C.E., Panchagnula V., Weerawardena A., Waddington L.J., Kennedy D.F., Drummond C.J. Lanthanide phytanates: liquid-crystalline phase behavior, colloidal particle dispersions, and potential as medical imaging agents. Langmuir 2010, 26(9):6240-6249.
20. Moghaddam M.J., de Campo L., Waddington L.J., Drummond C.J. Chelating phytanyl-EDTA amphiphiles: self-assembly and promise as contrast agents for medical imaging. Soft Matter 2010, 6(23):5915-5929.
21. Mulder W.J.M., Strijkers G.J., van Tilborg G.A.F., Griffioen A.W., Nicolay K. Lipid-based nanoparticles for contrast-enhanced MRI and molecular imaging. NMR Biomed 2006, 19(1):142-164.
22. Spicer P.T. Progress in liquid crystalline dispersions: cubosomes. Curr Opin Colloid Interface Sci 2005, 10(5-6):274-279.
23. Larsson K., Fontell K., Krog N. Structural relationships between lamellar, cubic and hexagonal phases in monoglyceride-water systems: possibility of cubic phases in biological systems. Chem Phys Lipids 1980, 27:321-328.
24. Hyde S.T., Andersson S., Ericsson B., Larsson K. Acubic structure consisting of a lipid bilayer forming an infinite periodic minimum surface of the gyroid type in the glycerolmonooleat-water system. ZKristallogr 1984, 168:213-219.
25. Gustafsson J., Ljusberg-Wahren H., Almgren M., Larsson K. Cubic lipid-water phase dispersed into submicron particles. Langmuir 1996, 12:4611-4613.
26. Andersson S., Jacob M., Lidin S., Larsson K. Structure of the cubosome-a closed lipid bilayer aggregate. ZKristallogr 1995, 210:315-318.
27. Wilcox C.S., Pearlman A. Chemistry and antihypertensive effects of tempol and other nitroxides. Pharmacol Rev 2008, 60(4):418-469.
28. Woldman Y.Y., Semenov S.V., Bobko A.A., Kirilyuk I.A., Polienko J.F., Voinov M.A., et al. Design of liposome-based pH sensitive nanospin probes: nano-sized particles with incorporated nitroxides. Analyst 2009, 134(5):904-910.
29. Swartz H.M. Use of nitroxides to measure redox metabolism in cells and tissues. JChem Soc, Faraday Trans 1987, 83(1):191-202.
30. Soule B.P., Hyodo F., Matsumoto K.I., Simone N.L., Cook J.A., Krishna M.C., et al. Therapeutic and clinical applications of nitroxide compounds. Antioxid Redox Signal 2007, 9(10):1731-1743.
31. Drummond C.J., Fong C. Surfactant self-assembly objects as novel drug delivery vehicles. Curr Opin Colloid Interface Sci 1999, 4(6):449-456.
32. Mulet X., Kennedy D.F., Conn C.E., Hawley A., Drummond C.J. High throughput preparation and characterisation of amphiphilic nanostructured nanoparticulate drug delivery vehicles. Int J Pharm 2010, 395(1, 2):290-297.
33. Seddon J.M., Squires A.M., Conn C.E., Ces O., Heron A.J., Mulet X., et al. Pressure-jump X-ray studies of liquid crystal transitions in lipids. Philos Trans R Soc London, Ser A 2006, 364(1847):2635-2655.
34. Muir B.W., Moffat B.A., Harbour P., Coia G., Zhen G.L., Waddington L., et al. Combinatorial discovery of novel amphiphilic polymers for the phase transfer of magnetic nanoparticles. JPhys Chem C 2009, 113(38):16615-16624.
35. Conn C.E., Mulet X., Moghaddam M.J., Darmanin C., Waddington L.J., Sagnella S.M., et al. Enhanced uptake of an integral membrane protein, the dopamine D2L receptor, by cubic nanostructured lipid nanoparticles doped with Ni(II) chelated EDTA amphiphiles. Soft Matter 2011, 7(2):567-578.
36. Glockner J.F., Chan H.C., Swartz H.M. Invivo oximetry using a nitroxide-liposome system. Magn Reson Med 1991, 20(1):123-133.
37. Chan H.C., Magin R.L., Swartz H.M. Delivery of nitroxide spin label to cultured cells by liposomes. Magn Reson Med 1988, 8(2):160-170.
38. Kinoshita Y., Yamada K., Yamasaki T., Mito F., Yamato M., Kosem N., et al. Invivo evaluation of novel nitroxyl radicals with reduction stability. Free Radic Biol Med 2010, 49(11):1703-1709.
39. Khan N., Blinco J.P., Bottle S.E., Hosokawa K., Swartz H.M., Micallef A.S. The evaluation of new and isotopically labeled isoindoline nitroxides and an azaphenalene nitroxide for EPR oximetry. JMagn Reson 2011, 211(2):170-177.
40. Davis R.M., Mitchell J.B., Krishna M.C. Nitroxides as cancer imaging agents. Anti-Cancer Agents Med Chem 2011, 11(4):347-358.
41. Matsumoto K. Utility decay rates of T1-weighted magnetic resonance imaging contrast based on redox-sensitive paramagnetic nitroxyl contrast agents. Biol Pharm Bull 2009, 32(4):711-716.
42. Gussoni M., Greco F., Ferruti P., Ranucci E., Ponti A., Zetta L. Poly(amidoamine)s carrying TEMPO residues for NMR imaging applications. New J Chem 2008, 32(2):323-332.
43. Briggs J., Chung H., Caffrey M. The temperature-composition phase diagram and mesophase structure characterization of the monoolein/water system. Journal De Physique Ii 1996, 6(5):723-751.
44. Rittman M., Frischherz M., Burgmann F., Hartley P.G., Squires A. Direct visualisation of lipid bilayer cubic phases using atomic force microscopy. Soft Matter 2010, 6(17):4058-4061.
45. Ananta J.S., Godin B., Sethi R., Moriggi L., Liu X.W., Serda R.E., et al. Geometrical confinement of gadolinium-based contrast agents in nanoporous particles enhances T1 contrast. Nature Nanotech 2010, 5(11):815-821.
46. Shen H.H., Crowston J.G., Huber F., Saubern S., McLean K.M., Hartley P.G. The influence of dipalmitoyl phosphatidylserine on phase behaviour of and cellular response to lyotropic liquid crystalline dispersions. Biomaterials 2010, 31(36):9473-9481.
47. Murgia S., Falchi A.M., Mano M., Lampis S., Angius R., Carnerup A.M., et al. Nanoparticles from lipid-based liquid crystals: emulsifier influence on morphology and cytotoxicity. JPhys Chem B 2010, 114(10):3518-3525.
48. Gong X.J., Moghaddam M.J., Sagnella S.M., Conn C.E., Mulet X., Danon S.J., et al. Nanostructured self-assembly materials from neat and aqueous solutions of C18 lipid pro-drug analogues of Capecitabine-a chemotherapy agent: focus on nanoparticulate cubosomes of the oleyl analogue. Soft Matter 2011, 7(12):5764-5776.
49. Fong C., Weerawardena A., Sagnella S.M., Mulet X., Krodkiewska I., Chong J., et al. Monodisperse nonionic isoprenoid-type hexahydrofarnesyl ethylene oxide surfactants: high throughput lyotropic liquid crystalline phase determination. Langmuir 2011, 27(6):2317-2326.
50. Dong Y.-D., Larson I., Bames T.J., Prestidge C.A., Boyd B.J. Adsorption of nonlamellar nanostructured liquid-crystalline particles to biorelevant surfaces for improved delivery of bioactive compounds. ACS Appl Mater Interfaces 2011, 3(5):1771-1780.
51. Kaminskas L.M., McLeod V.M.H., Porter C.J., Boyd B.J. Differences in colloidal structure of pegylated nanomaterials dictate the likelihood of accelerated blood clearance. JPharm Sci 2011, 100(11):5069-5077.
52. Allen T.M., Hansen C., Rutledge J. Liposomes with prolonged circulation times: factors affecting uptake by reticuloendothelial and other tissues. Biochim Biophys Acta 1989, 981(1):27-35.